And our results confirmed that the prevalence of CAFs was closely associated with the metastatic potential of gastric cancer, and further work should be done to confirm the correlation between CAFs’ prevalence and survival Selisistat cell line of gastric cancer patients. Conclusions Our findings report here demonstrate that reactive cancer associated fibroblasts (CAFs) were frequently accumulated in gastric cancer tissues, and the prevalence of CAFs was correlated with tumor size, depth of the tumor and tumor metastasis as well as the overall TNM stage, suggesting that CAFs were critical for tumor growth, invasion and metastasis, thus give some supports for the prognosis of
the gastric cancer patients. Acknowledgements We want to thank Prof. Li Gao in the Department of pathology of Changhai Hospital and Dr. Ni Zhu in the Central Lab of Changhai Hospital for their expert technical supports for the experiments. This work was supported by The National Natural Science Foundation of China (30672046). References 1. Anderson C, Nijagal A, Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006, 10:345–352.PubMed 2. Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL: Sabiston Textbook of Surgery. 18th edition. Saunders, An Imprinter of Elsevier. Philadelphia; 2008.
3. Kim JW, Hwang I, Kim MJ, Jang SJ: Clinicopathological characteristics DMXAA manufacturer and predictive markers of early gastric cancer with recurrence. J Korean Med Sci 2009, 24:1158–1164.PubMedCrossRef 4. Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya
N, Itoh A, Hirooka Y, Goto Florfenicol H: Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007, 22:1435–1442.PubMedCrossRef 5. Aurello P, D’Angelo F, Rossi S, Bellagamba R, Cicchini C, Nigri G, Ercolani G, De Angelis R, Ramacciato G: Classification of lymphnode metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. Am Surg 2007, 73:359–366.PubMed 6. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392–401.PubMedCrossRef 7. Mueller MM, Fusenig NE: Crenigacestat manufacturer Friends or foes – bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839–849.PubMedCrossRef 8. Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332–337.PubMedCrossRef 9. Tlsty TD, Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119–150.PubMedCrossRef 10. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG: No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008, 40:650–655.PubMedCrossRef 11.